INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,808,000 | +80.6% | 54,942 | -3.3% | 0.53% | +138.9% |
| Q3 2019 | $3,769,000 | -16.6% | 56,794 | 0.0% | 0.22% | +10.0% |
| Q2 2019 | $4,519,000 | -31.0% | 56,794 | -12.6% | 0.20% | -9.5% |
| Q4 2018 | $6,547,000 | -20.2% | 64,961 | 0.0% | 0.22% | +40.5% |
| Q3 2018 | $8,208,000 | +50.6% | 64,961 | 0.0% | 0.16% | +66.3% |
| Q2 2018 | $5,451,000 | +36.4% | 64,961 | 0.0% | 0.10% | +18.8% |
| Q1 2018 | $3,996,000 | – | 64,961 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |